[go: up one dir, main page]

WO2008099781A1 - アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤 - Google Patents

アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤 Download PDF

Info

Publication number
WO2008099781A1
WO2008099781A1 PCT/JP2008/052138 JP2008052138W WO2008099781A1 WO 2008099781 A1 WO2008099781 A1 WO 2008099781A1 JP 2008052138 W JP2008052138 W JP 2008052138W WO 2008099781 A1 WO2008099781 A1 WO 2008099781A1
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic
prophylactic agent
demyelinating disease
amino alcohol
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/052138
Other languages
English (en)
French (fr)
Inventor
Kazuhiko Kuriyama
Tokutarou Yasue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Priority to US12/449,517 priority Critical patent/US20100093745A1/en
Priority to JP2008558073A priority patent/JP5198293B2/ja
Publication of WO2008099781A1 publication Critical patent/WO2008099781A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

【課題】　新規な脱髄性疾患の治療剤又は予防剤を提供する。 【解決手段】　一般式（１） で表されるスフィンゴシン－１－燐酸受容体アゴニストであるアミノアルコール誘導体、薬理学的に許容されるその塩又はそれらの水和物は脱髄性疾患の治療剤又は予防剤。
PCT/JP2008/052138 2007-02-13 2008-02-08 アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤 Ceased WO2008099781A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/449,517 US20100093745A1 (en) 2007-02-13 2008-02-08 Therapeutic agent or prophylactic agent for demyelinating disease comprising amino alcohol derivative as active ingredient
JP2008558073A JP5198293B2 (ja) 2007-02-13 2008-02-08 アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007031718 2007-02-13
JP2007-031718 2007-02-13

Publications (1)

Publication Number Publication Date
WO2008099781A1 true WO2008099781A1 (ja) 2008-08-21

Family

ID=39690014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052138 Ceased WO2008099781A1 (ja) 2007-02-13 2008-02-08 アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤

Country Status (3)

Country Link
US (1) US20100093745A1 (ja)
JP (1) JP5198293B2 (ja)
WO (1) WO2008099781A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009142195A1 (ja) * 2008-05-20 2009-11-26 杏林製薬株式会社 寛解導入維持剤
WO2010042998A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
US8592399B2 (en) 2008-10-17 2013-11-26 Akaal Pharma Pty Ltd. S1P receptors modulators and their use thereof
JP2014523887A (ja) * 2011-07-06 2014-09-18 中国医学科学院薬物研究所 アミノプロパンジオール誘導体、準備、および医薬品組成物および用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006068A1 (en) * 1994-08-22 1996-02-29 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and medicinal use thereof
WO2004026817A1 (ja) * 2002-09-19 2004-04-01 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
WO2006129688A1 (ja) * 2005-05-31 2006-12-07 Mitsubishi Pharma Corporation ２－アミノブタノール化合物及びその医薬用途
WO2006137509A1 (ja) * 2005-06-24 2006-12-28 Daiichi Sankyo Company, Limited Ｐｐａｒ調節剤を含有する医薬組成物
WO2007028821A2 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases
WO2007043433A1 (ja) * 2005-10-07 2007-04-19 Kyorin Pharmaceutical Co., Ltd. ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174029A1 (en) * 2006-08-08 2011-09-29 Kyorin Seiyaku Kk Aminoalcohol derivative and immunosuppressant containing the same as active ingredient

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006068A1 (en) * 1994-08-22 1996-02-29 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and medicinal use thereof
WO2004026817A1 (ja) * 2002-09-19 2004-04-01 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
WO2006129688A1 (ja) * 2005-05-31 2006-12-07 Mitsubishi Pharma Corporation ２－アミノブタノール化合物及びその医薬用途
WO2006137509A1 (ja) * 2005-06-24 2006-12-28 Daiichi Sankyo Company, Limited Ｐｐａｒ調節剤を含有する医薬組成物
WO2007028821A2 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases
WO2007043433A1 (ja) * 2005-10-07 2007-04-19 Kyorin Pharmaceutical Co., Ltd. ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
WO2009142195A1 (ja) * 2008-05-20 2009-11-26 杏林製薬株式会社 寛解導入維持剤
WO2010042998A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
US8592399B2 (en) 2008-10-17 2013-11-26 Akaal Pharma Pty Ltd. S1P receptors modulators and their use thereof
US9181182B2 (en) 2008-10-17 2015-11-10 Akaal Pharma Pty Ltd S1P receptors modulators
US9193716B2 (en) 2008-10-17 2015-11-24 Akaal Pharma Pty Ltd. S1P receptors modulators and their use thereof
US9707205B2 (en) 2008-10-17 2017-07-18 Akaal Pharma Pty Ltd. S1P receptors modulators and their use thereof
JP2014523887A (ja) * 2011-07-06 2014-09-18 中国医学科学院薬物研究所 アミノプロパンジオール誘導体、準備、および医薬品組成物および用途

Also Published As

Publication number Publication date
US20100093745A1 (en) 2010-04-15
JPWO2008099781A1 (ja) 2010-05-27
JP5198293B2 (ja) 2013-05-15

Similar Documents

Publication Publication Date Title
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
CA2661102C (en) Thiophene derivatives as s1p1/edg1 receptor agonists
TW200728307A (en) Novel spirochromanone derivatives
WO2010122980A8 (ja) 新規甲状腺ホルモンβ受容体作動薬
WO2009051119A1 (ja) ピリミジルインドリン化合物
MY148703A (en) Polycyclic cinnamide derivatives
WO2006053255A3 (en) Novel betulin derivatives, preparation thereof and use thereof
WO2009074950A3 (en) Thiophene derivatives as agonists of s1p1/edg1
WO2007121921A3 (en) Purine derivatives for use as adenosin a2a receptor agonists
WO2007150026A3 (en) Purinone derivatives as hm74a agonists
WO2007109578A3 (en) Substituted gamma lactams as prostaglandin ep2 agonists
WO2009090670A3 (en) Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same
CA2665931C (en) Hydrobenzamide derivatives as inhibitors of hsp90
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
WO2008006795A3 (en) Indole compounds
WO2011025982A3 (en) Tetracycline compounds
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
EA022994B1 (ru) Способ подавления толерантности к опиоидному анальгетику
WO2009047499A3 (en) Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
WO2008099781A1 (ja) アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2010132670A3 (en) Pentacycline compounds
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2008133297A1 (ja) ジスキネジアの治療または予防剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711017

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008558073

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12449517

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08711017

Country of ref document: EP

Kind code of ref document: A1